Shares of Crescent Biopharma Inc. (CBIO), an oncology company, began trading on the Nasdaq Capital Market on June 16, 2025, following a reverse merger with GlycoMimetics Inc. (Nasdaq: GLYC).
Crescent's investigational cancer programs feature a dual-action antibody as a core treatment, plus antibody-drug conjugates that can work alone or alongside its investigational immunotherapy. The lead drug candidate is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com